Gefitinib長期投与後の獲得耐性が疑われた進行肺腺癌に対しGEM(塩酸ゲムシタビン)+VNR(ビノレルビン)が奏効した1例

文献

J-GLOBAL ID：201002206603633148 整理番号：10A0839333

A Patient with Advanced Lung Adenocarcinoma Effectively Treated with Gemcitabine Plus Vinorelbine After Failure with Gefitinib

出版者サイト複写サービスで全文入手 {{ this.onShowCLink("http://jdream3.com/copy/?sid=JGLOBAL&noSystem=1&documentNoArray=10A0839333&COPY=1") }}
高度な検索・分析はJDreamⅢで {{ this.onShowJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A0839333&from=J-GLOBAL&jstjournalNo=Y0006A") }}

著者 (4件)： , , ,
資料名：
巻： 50 号： 3 ページ： 297-302 (J-STAGE) 発行年： 2010年
JST資料番号： Y0006A ISSN： 0386-9628 資料種別：逐次刊行物 (A)
記事区分：短報発行国：日本 (JPN) 言語：日本語 (JA)

背景.Gefitinibは非小細胞肺癌の10~20%の症例で...

,...
,...

続きはJDreamIII（有料）にて {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=10A0839333&from=J-GLOBAL&jstjournalNo=Y0006A") }}

抗腫よう薬の臨床への応用 , 抗腫よう抗生物質の臨床への応用 , 腫ようの薬物療法 , 呼吸器の腫よう

, ,

引用文献 (15件)：

1. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J Clin Oncol. 2003; 21: 2237-2246.
2. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer. 2004; 45: 93-104.
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129-2139.
4. Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497-1500.
5. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003; 21: 3025-3034.

, , , , , ,

前のページに戻る